Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab versus placebo for psychosis and/or obsessive-compulsive disorder with suspected immune involvement
2019-000256-33Phase 2Active
- Sponsor
- Akademiska sjukhuset
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rituximab in Schizophrenia Spectrum Disorders (SSD) and obsessive compulsive disorder (OCD) (2 arms), sponsored by Akademiska sjukhuset. Primary endpoint: Primary efficacy endpoint. Started May 2019; status: active.
02
Drugs
rituximab
03
Conditions
Schizophrenia Spectrum Disorders (SSD)obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on 2019-000256-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000256-33.